Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control.

Thornton, V; Lennon, D; Rasanathan, K; O'Hallahan, J; Oster, P; Stewart, J; Tilman, S; Aaberge, I; Feiring, B; Nokleby, H; Rosenqvist, E; White, K; Reid, S; Mulholland, K; Wakefield, M J; Martin, D

Thornton, V; Lennon, D; Rasanathan, K; O'Hallahan, J; Oster, P; Stewart, J; Tilman, S; Aaberge, I; Feiring, B; Nokleby, H; Rosenqvist, E; White, K; Reid, S; Mulholland, K; Wakefield, M J; Martin, D.

Affiliation

Thornton V; The University of Auckland, Meningococcal B Project, P.O. Box 98847, South Auckland Mail Centre, Auckland, New Zealand.

Vaccine ; 24(9): 1395-400, 2006 Feb 27.

Article in En | MEDLINE | ID: mdl-16242221

Subject(s)

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Meningococcal Vaccines / Meningococcal Infections Type of study: Clinical_trials Limits: Adolescent / Adult / Humans / Middle aged Country/Region as subject: Oceania Language: En Journal: Vaccine Year: 2006 Document type: Article Affiliation country: Nueva Zelanda Country of publication: Países Bajos

Search on Google

Add to My VHL

XML

PubMed Links